Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial

This is a phase Ib trial that studies personalized network pharmacology-based drug repurposing in patients with advanced thyroid cancer who have no other treatment options. The main objective is to study if it is feasible to give patients individualized drug combinations selected based on their tumor genetic profile. The secondary objective is to find out whether these treatments are safe and can help control the growth of the patient tumors or stop them from getting worse.

Trial Details

NCT ID
NCT07485569
Phase
PHASE1
Sponsor
Radboud University Medical Center
Status
RECRUITING
Cancer Type
Thyroid Cancer
Interventions
  • Personalised treatment
Locations (sample)
  • Nijmegen, Netherlands|51.8425,5.85278

Key Eligibility Criteria

  • Patients with locally advanced or metastatic TC (such as ATC, PDTC, and RAI refractory DTC progressive under treatment with multikinase inhibitors)…
  • Prior anticancer treatment-related toxicities resolved to Grade ≤1 (CTCAE v5.0).
  • Measurable disease per RECIST 1.1
  • ECOG performance status ≤ 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Thyroid Cancer Trials on Trialify →